A new diabetes vaccine approach shows promise by selectively neutralizing antigens while leaving the rest of the immune system unaffected.


Continue Reading

A phase 2 study of the vaccine product (TOL-3021) has yielded some impressive findings.

John Schieszer has the latest on the story in today’s Medical Minute.